Iterum CMO Sailaja Puttagunta resigns effective May 31; Steven Aronin to lead clinical development

Iterum Therapeutics plc

CMO Sailaja Puttagunta resigns for personal reasons, effective May 31, 2024; no disagreement with company.
Dr. Puttagunta will remain as consultant during regulatory review of oral sulopenem NDA for uncomplicated UTI.
Steven Aronin, SVP and Head of Clinical Development, will assume leadership of development and regulatory activities.
Transition occurs during FDA review of resubmitted NDA for oral sulopenem; potential impact on timeline.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sailaja Puttagunta

Chief Medical Officer

ITRMF · Iterum Therapeutics plc

Effective: 2024-05-31
Filed: May 10, 2024, 7:59 PM ET

On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc (the “Company”) of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sailaja Puttagunta resigned as Chief Medical Officer at Iterum Therapeutics plc.

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On May 8, 2024, Sailaja Puttagunta M.D. notified Iterum Therapeutics plc (the “Company”) of her decision to resign as Chief Medical Officer the Company, effective May 31, 2024.

View on SEC.gov

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-24-057831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.